You are here

Category
Technology Name
Briefcase
Scientist
169
Monoclonal antibodies for peptide and steroid hormones Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products. Steroid Hormones: §  119, 169 –...

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

Steroid Hormones:

§  119, 169 – Monoclonal antibodies to Testosterone          

      Description: Rat monoclonal antibodies raised against testosterone 3-(0-   carboxymethyl)oxime-BSA. Available clones: 5F2, 5A4.

Testosterone is the principal male sex hormone and an anabolic steroid. In mammals, testosterone is secreted primarily in the testicles of males and the ovaries of females, although small amounts are also secreted by the adrenal glands.

Reference: Kohen F, Lichter S, Eshhar Z, Lindner HR. 1982. Preparation of monoclonal antibodies able to discriminate between testosterone and 5 alpha-dihydrotestosterone. Steroids. 39(4):453-9.

+
  • Dr. Gad Lavie
279
  • Prof. Joel L. Sussman
141
Monoclonal antibodies for peptide and steroid hormones Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.   §  127, 274, 141 – Monoclonal...

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

 

§  127, 274, 141 – Monoclonal antibodies to estradiol         

      Description: Monoclonal antibodies raised against oestradiol-6-     carboxymethyl oxime-BSA. Available clones: 2F9 (Rat, IgG2a), 15 (IgG2b),    8D9 (IgG2a).

Estradiol is a sex hormone, which has not only a critical impact on reproductive and sexual functioning, but also affects other organs, including the bones. In the female, estradiol acts as a growth hormone for tissues of the reproductive organs.

            References: De Boever J, Kohen F, Usanachitt C, Vandekerckhove D, Leyseele D, Vandewalle L. 1986. Direct chemiluminescence immunoassay for estradiol in serum. Clin Chem. 32(10):1895-900.

            S?mjen D1, Amir-Zaltsman Y, Mor G, Gayer B, Lichter S, Nevo N, Kohen F. 1998. A monoclonal antibody to oestradiol potentiates the stimulation of the specific activity of the brain type creatine kinase by oestrogen in vivo and in vitro. J Steroid Biochem Mol Biol. 64(5-6):297-304.

+
  • Dr. Fortune Kohen
236
236-237 - Diastereomer Lytic Peptides for Treatment of Solid Tumors and Metastasis Description: 15-mer (Leu-Lys-Dleu- Leu-Lys-Dlys-Leu-Dleu-Dlys-Lys-Leu-Leu-Dlys-Leu-Leu) and 15-mer Histidin (H-Leu-Lys-D-Leu- Leu-His-D-Lys-Leu-D-Leu-D-Lys-His-Leu-Leu-D-Lys-Leu-Leu-NH2) are membrane-active peptides...

236-237 - Diastereomer Lytic Peptides for Treatment of Solid Tumors and Metastasis

Description: 15-mer (Leu-Lys-Dleu- Leu-Lys-Dlys-Leu-Dleu-Dlys-Lys-Leu-Leu-Dlys-Leu-Leu) and 15-mer Histidin (H-Leu-Lys-D-Leu- Leu-His-D-Lys-Leu-D-Leu-D-Lys-His-Leu-Leu-D-Lys-Leu-Leu-NH2) are membrane-active peptides composed of both D- and L amino acids (diastereomers). These peptides have demonstrated potent anti-cancer and anti metastatic activities in several animal models including models for prostate and lung cancer. They were shown to successfully inhibit tumor growth when injected intratumorally or intraveneously. The 15-mer Histidine form shows reduced systemic toxicity.

References: Papo N, Braunstein A, Eshhar Z, Shai Y. 2004. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. 64(16):5779-86.

Makovitzki A1, Fink A, Shai Y. 2009. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res. 69(8):3458-63.

+
  • Prof. Yechiel Shai
261
261 - Monoclonal antibody to GluR3B Description: Mouse monoclonal antibody (IgG2a), raised against a synthetic peptide of the Glutamate receptor (GluR3B), corresponding to amino acids 383-395 (NEYERFVPFSDQQISNDSSSSENR) of Leishmania donovani GluR3B. May be used for diagnosis as well as drug...

261 - Monoclonal antibody to GluR3B

Description: Mouse monoclonal antibody (IgG2a), raised against a synthetic peptide of the Glutamate receptor (GluR3B), corresponding to amino acids 383-395 (NEYERFVPFSDQQISNDSSSSENR) of Leishmania donovani GluR3B.

May be used for diagnosis as well as drug development for "autoimmune epilepsy”, a condition characterized by high levels of neuropathogenic human anti-GluR3B in serum and CSF.

+
  • Dr. Mia Levite
  • Prof. Vivian I. Teichberg
118
  Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry. Leukotrienes:   Drugs: §  118 - Monoclonal antibody to Buserelin      Description: Rat...

 

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

Leukotrienes:

 

Drugs:

§  118 - Monoclonal antibody to Buserelin

     Description: Rat monoclonal antibodies raised against Buserelin.

     Available clone: 8B4, IgG1.

 
+
  • Dr. Fortune Kohen
176
176-177 - Monoclonal antibodies to phospho-ERK/Map Kinase Description: Monoclonal antibodies raised against peptides containing the 11 amino acids, HTGFLTEYVAT, corresponding to the ERK activation loop either Tyr -phosphorylated (ERK-PY193), or Thr-phosphorylated (ERK-PT115). ERK belongs to the...

176-177 - Monoclonal antibodies to phospho-ERK/Map Kinase

Description: Monoclonal antibodies raised against peptides containing the 11 amino acids, HTGFLTEYVAT, corresponding to the ERK activation loop either Tyr -phosphorylated (ERK-PY193), or Thr-phosphorylated (ERK-PT115).

ERK belongs to the family of mitogen-activated protein kinases (MAPKs) and is an important component in many intracellular signaling events. ERK is phosphorylated and activated by the upstream kinases, MEK1 and MEK2 on regulatory Threonin (Thr) and tyrosine (Tyr) residues, which are localized in the activation loop of ERK.

Reference: Yao Z, Dolginov Y, Hanoch T, Yung Y, Ridner G, Lando Z, Zharhary D, Seger R. 2000. Detection of partially phosphorylated forms of ERK by monoclonal antibodies reveals spatial regulation of ERK activity by phosphatases. FEBS Lett. 468(1):37-42.

+
  • Prof. Rony Seger
238
238 - CP Peptide Description: Core peptide (CP; GLRILLLKV-D-stereoisomer), a synthetic peptide coding for the transmembrane domain of the ?-subunit of the T-cell receptor (TCR), a region that has been identified to be crucial for the assembly and function of the TCR. Was shown to significantly inhibit...

238 - CP Peptide

Description: Core peptide (CP; GLRILLLKV-D-stereoisomer), a synthetic peptide coding for the transmembrane domain of the ?-subunit of the T-cell receptor (TCR), a region that has been identified to be crucial for the assembly and function of the TCR.

Was shown to significantly inhibit T-cell-mediated inflammation upon subcutaneously administration in animal models. Has the potential of being used as an alternative therapy for immunosuppression.

Reference: Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. 2005. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J. 19(9):1190-2.

+
  • Prof. Yechiel Shai
295
295 – Milstein catalyst Description: Carbonylhydrido[6-(di-t-butyl-phosphinomethylene)-2-(N,N-diethylaminomethyl)-1,6-dihydropyridine]ruthenium(II). Ruthenium-based catalyst that converts amines and alcohols into amides. Reference: Chidambaram Gunanathan, Yehoshoa Ben-David, David Milstein. 2007....

295 – Milstein catalyst

Description: Carbonylhydrido[6-(di-t-butyl-phosphinomethylene)-2-(N,N-diethylaminomethyl)-1,6-dihydropyridine]ruthenium(II).

Ruthenium-based catalyst that converts amines and alcohols into amides.

Reference: Chidambaram Gunanathan, Yehoshoa Ben-David, David Milstein. 2007. Direct Synthesis of Amides from Alcohols and Amines with Liberation of H2. Science

317(5839):790-2.

+
  • Prof. David Milstein
143
Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry. Leukotrienes: Drugs: §  143 - Monoclonal antibody to Medroxy-progesterone-acetate     ...

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

Leukotrienes:

Drugs:

§  143 - Monoclonal antibody to Medroxy-progesterone-acetate

     Description: Rat monoclonal antibodies raised against Medroxy-progesterone- acetate(MPA)-3-carboxymethyl oxime- BSA. Available clone: 1F5, IgG1.

     Medroxy-progesterone-acetate (MPA) is a highly potent progestational steroid that has been used worldwide as a contraceptive.

+
  • Dr. Fortune Kohen
265
Monoclonal antibodies specific to cholesterol/ceramide mixture Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes. Originally raised against an artificial monolayer of lipid...

Monoclonal antibodies specific to cholesterol/ceramide mixture

Description: Monoclonal antibodies specific for cholesterol/ceramide-rich domains (clones 405F, 14F, 499F) and cholesterol micro-domains (clones 36A1, 5881) in cell membranes.

Originally raised against an artificial monolayer of lipid mixtures in, and were shown to specifically label the above domains in different cell membranes.

Reference:  Scheffer L, Futerman AH, Addadi L. 2007. Antibody labeling of cholesterol/ceramide ordered domains in cell membranes. Chembiochem 8(18):2286-94.

+
  • Prof. Lia Addadi
120
Monoclonal antibodies raised against bFSH. Available clone: 1G12. Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.Reference: Somjen D1,...

Monoclonal antibodies raised against bFSH. Available clone: 1G12.
Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.
Reference: Somjen D1, Tordjman K, Kohen F, Baz M, Razon N, Ouaknine G, Stern N. 1997. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 46(5):555-62.

Monoclonal antibodies for peptide and steroid hormones

Due to their high specificity and sensitivity these antibodies may be applicable for research, diagnosis and therapeutics. A particular use may be quality control of industrial manufacturing of food products.

 

Peptide Hormones:

§  120 – Monoclonal antibody to FSH

Description: Monoclonal antibodies raised against bFSH. Available clone: 1G12.

Follicle-stimulating hormone (FSH) is synthesized and secreted by gonadotrophs of the anterior pituitary gland. FSH regulates the development, growth, pubertal maturation and reproductive processes of the body.

      Reference: Somjen D1, Tordjman K, Kohen F, Baz M, Razon N, Ouaknine G, Stern N. 1997. Combined beta FSH and beta LH response to TRH in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 46(5):555-62.


 

+
  • Dr. Fortune Kohen
179
179 - Allyl-mercapto-captopril (CPSSA - Captosal) Description: Conjugation between allicin (the biologically active molecule in garlic) and captopril, a known antihypertensive drug. Was shown to offer therapeutic benefits for the treatment of the metabolic syndrome, as demonstrated by various animal...

179 - Allyl-mercapto-captopril (CPSSA - Captosal)

Description: Conjugation between allicin (the biologically active molecule in garlic) and captopril, a known antihypertensive drug. Was shown to offer therapeutic benefits for the treatment of the metabolic syndrome, as demonstrated by various animal models. These include improvement of glucose tolerance, preventing weight gain, lowering blood pressure, reducing cardiac hypertrophy and potent antioxidant activities.

Reference: Miron T, Rabinkov A, Peleg E, Rosenthal T, Mirelman D, Wilcheck M. 2004. Allylmercaptocaptopril: a new antihypertensive drug. Am. J. Hypertens. 1:71-73.

+
  • Prof. David Mirelman
1655
Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and...

Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and promote a number of pathological conditions. Therefore the elimination of senescent cells is desired in order to prevent tumor- and inflammation- related pathologies and also to inhibit tissue ageing.
Today, our understanding of the mechanisms regulating the viability of senescent cells is limited. It has been suggested that senescent cells are resistant to apoptosis. Therefore, senescent cells elimination may be achieved by modifying the resistance to apoptosis of these cells.
Here the researches demonstrate the first feasible therapeutic approach that leads to eradication of senescent cells. Combination of direct induction of apoptosis in senescent cells with induction of cell death by pro-inflammatory repose induce by p21 knockdown will lead to reduction of viable senescent cells.

Applications


  • A therapeutic impact on inflammatory and fibrotic disease
  • Therapy for age-related disease such as type 2 diabetes, Alzheimer’s disease, Atherosclerosis, cataracts, Chronic obstructive pulmonary disease (COPD), and Osteoporosis

Advantages


  • Effective elimination of senescent cells- removal of senescent cells can prevent or delay tissue dysfunction and extend health span
  • Does not damage normal cells even at high concentrations

Technology's Essence


Researches demonstrated that the anti-apoptotic proteins Bcl-xL and Bcl-w level were elevated in senescence cells of both human and mouse origin. A subsequent study, in which Bcl-xL and Bcl-w were knocked down by siRNA, revealed that a combined knock down of Bcl-xL and Bcl-w had synergic effect, resulting in reduction of 50% in cell viability. Thus the increased level of anti-apoptotic proteins Bcl-xL and Bcl-w may account for the apoptotic resistance of senescent cells. p21 knockdown induced pro-inflammatory response and cell death in senescent cells.
Overall, the researchers show that combined inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-w allows specific elimination of senescent cells and might be used to treat diseases where senescent cells are present. The researchers also found that the same effect might be achieved by reducing the expression of p21 in senescent cells. Integrating both approaches propose a more effective therapy.

+
  • Ph.D. Valery Krizhanovsky
1698
GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (...

GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (nGD), affect 4% of GD patients and additionally include neurological symptoms. Type 1 patients can have a normal life expectancy if treated whereas type 2/3 patients do not survive to reach adulthood. Moreover, GD carriers, approximately 1% of the population, are in a major risk of developing Parkinson’s disease. Current therapies suffer from severe drawbacks in the treatment of type 1 GD and no therapy exists that effectively treat nGD. The present technology offers a novel therapeutic target for the treatment of Gaucher's disease (GD) which addresses also the neurological symptoms.

Applications


  • Alternative treatment for type 1 GD
  • First line therapy for nGD

Advantages


  • A novel therapy for nGD which has no treatment for the present.
  • A novel therapeutic approach for GD type 1, via a previously unknown molecular mechanism.
  • Allows the development of an orally administered treatment, far more convenient for the patients than the existing treatments.
  • Reduced costs compared to the existing therapies of ERP or BMT

Technology's Essence


The proposed technology is based on the discovery that RIP3 is a key player in the manifestation of GD and that inhibiting RIP3 activity is effectively ameliorating the symptoms of GD not only in the less severe type 1 but also in the neuropathic form of the disease, types 2 and 3. nGD is associated with a massive neuronal loss and elevated RIP3 levels. Inhibition of RIP3 in a mouse model of nGD resulted in a dramatic attenuation of disease signs: drastic extension of life span, no weight loss, improvements in motor coordination, reduced neuroinflammation and improved liver and spleen injuries.

+
  • Prof. Anthony H. Futerman

Pages